When does belsomra go generic?

Short answer: There isn’t a generic Belsomra (suvorexant) available in the U.S. right now, and there’s no fixed year when one will appear. Generic timing depends on patent protections and regulatory exclusivities, which can keep generics out for many years.

What affects the timeline
- Patent protection: Belsomra is protected by multiple patents (and potentially other regulatory protections). Generic entry can’t happen until all listed patents expire or are invalidated.
- Regulatory exclusivity: In addition to patents, there can be orphan or other exclusivities that delay generics.
- Litigation/settlements: Patent disputes or settlements can push the first generic launch later or, in some cases, create agreed-upon launch dates.

What to check for up-to-date info
- FDA Orange Book (Patent and Exclusivity data): Look up suvorexant to see the listed patents and their expiration dates, and whether a “First Generic” has been designated.
- If you’re outside the U.S., check your country’s drug regulatory authority for local patent status and generic approvals.

If you’d like, I can guide you through finding the current Orange Book entry for suvorexant or summarize the latest official dates once you share your country.